Journal of the American Academy of Dermatology · 2025
Risk factors for recurrence or relapse after a first episode of adult IgA vasculitis: A multicenter retrospective study.
СтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lutz William, Hua Camille, Mariotti Elena Biancamaria, Terrier Benjamin, Dupin Nicolas, Aractingi Selim, Bouaziz Jean-David, Jachiet Marie, Grolleau Chloé, Bettuzzi Thomas
Аннотация
BACKGROUND: Adult immunoglobulin A vasculitis (IgAV) course is variable, and its prognostic factors are poorly understood.
OBJECTIVES: To identify risk factors for IgAV recurrence/relapse in adults.
METHODS: We included adult patients with IgAV between January 2016 and July 2022. The primary outcome was the time to recurrence/relapse. Factors associated with recurrence/relapse were assessed with hazard ratios (HR) and 95% confidence intervals (CI). Treatment effectiveness was assessed using inverse probability of treatment weighting.
RESULTS: A total of 229 patients were included. Abdominal purpura and articular involvement were associated with a higher risk of recurrence/relapse (HR: 2.03 [95%CI: 1.16-3.58]; P = .014; HR: 2.29 [95%CI: 1.25-4.20]; P = .0074, respectively), as well as fever at diagnosis (HR: 3.54 [95%CI: 1.19-10.5]; P = .023]). Factors associated with lower risk were post-bacterial cause (HR: 0.26 [95%CI: 0.07-0.93]; P = .039) and systemic corticosteroids administration (HR: 0.30 [95%CI: 0.12-0.75]; P = .0098). In the inverse probability of treatment weighting analysis, corticosteroids were still associated with a reduced risk of recurrence/relapse (HR: 0.41 [95%CI: 0.18-0.93]; P = .03), whereas colchicine was not (HR: 0.84 [95%CI: 0.42-1.69]; P = .63).
LIMITATIONS: Retrospective design.
CONCLUSION: Systemic corticosteroid administration and post-bacterial etiology appear to protect against recurrence/relapse in adult IgAV. Conversely, fever at diagnosis, abdominal purpura, and articular involvement may be associated with an increased risk.
OBJECTIVES: To identify risk factors for IgAV recurrence/relapse in adults.
METHODS: We included adult patients with IgAV between January 2016 and July 2022. The primary outcome was the time to recurrence/relapse. Factors associated with recurrence/relapse were assessed with hazard ratios (HR) and 95% confidence intervals (CI). Treatment effectiveness was assessed using inverse probability of treatment weighting.
RESULTS: A total of 229 patients were included. Abdominal purpura and articular involvement were associated with a higher risk of recurrence/relapse (HR: 2.03 [95%CI: 1.16-3.58]; P = .014; HR: 2.29 [95%CI: 1.25-4.20]; P = .0074, respectively), as well as fever at diagnosis (HR: 3.54 [95%CI: 1.19-10.5]; P = .023]). Factors associated with lower risk were post-bacterial cause (HR: 0.26 [95%CI: 0.07-0.93]; P = .039) and systemic corticosteroids administration (HR: 0.30 [95%CI: 0.12-0.75]; P = .0098). In the inverse probability of treatment weighting analysis, corticosteroids were still associated with a reduced risk of recurrence/relapse (HR: 0.41 [95%CI: 0.18-0.93]; P = .03), whereas colchicine was not (HR: 0.84 [95%CI: 0.42-1.69]; P = .63).
LIMITATIONS: Retrospective design.
CONCLUSION: Systemic corticosteroid administration and post-bacterial etiology appear to protect against recurrence/relapse in adult IgAV. Conversely, fever at diagnosis, abdominal purpura, and articular involvement may be associated with an increased risk.